Rigel Pharmaceuticals (RIGL) Accumulated Depreciation & Amortization (2010 - 2025)

Rigel Pharmaceuticals has reported Accumulated Depreciation & Amortization for 16 years, with the latest figure at $2.4 million in Q4 2025.

• For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 8.39% year-over-year to $2.4 million; the trailing twelve-month figure through Dec 2025 stood at $2.4 million (up 8.39% YoY), and the FY2025 full-year result was $2.4 million, up 8.39% from the prior year.
• Accumulated Depreciation & Amortization for Q4 2025 stood at $2.4 million, up from $2.2 million in the prior quarter.
• The five-year high for Accumulated Depreciation & Amortization was $2.4 million in Q4 2025, with the low at $900000.0 in Q4 2022.
• Average Accumulated Depreciation & Amortization over 5 years is $1.6 million, with a median of $1.2 million recorded in 2023.
• Year-over-year, Accumulated Depreciation & Amortization fell 25.0% in 2022 and surged 79.97% in 2024.
• Tracing RIGL's Accumulated Depreciation & Amortization over 5 years: stood at $1.2 million in 2021, then slipped by 25.0% to $900000.0 in 2022, then soared by 37.56% to $1.2 million in 2023, then surged by 79.97% to $2.2 million in 2024, then increased by 8.39% to $2.4 million in 2025.
• The last three Accumulated Depreciation & Amortization figures came in at $2.4 million (Q4 2025), $2.2 million (Q4 2024), and $1.2 million (Q4 2023), per Business Quant data.

Peer Comparison